Conclusion HLA DR4 is an important index for determining RA prognosis.
结论HLA DR 4可作为判断RA治疗的重要预后指标。
Immunohistochemistry and FCM were used to detect the expression of TRAIL and its death receptors (DR4 and DR5).
免疫组化和流式细胞术检测肾脏TRAIL基因及其死亡受体DR 4、DR5的蛋白表达。
The expression of cell surface-bound DR4 and DR5 were determined by indirect fluorescence staining and flow cytometry analysis.
用间接免疫荧光染色结合流式细胞技术检测细胞表面DR4和DR5分子表达；
Conclusion This method is rapid, simple and accurate and is useful for matching type of HLA DRB1 alleles of DR4 positive donor and recipient in renal allograft.
结论本方法快速、简便、精确，可为肾移植中DR 4阳性供受者HLADRB1等位基因的配型提供可靠的方法。
Methods Immunohistochemistry and in situ quantification methods were used to observe the expression and the variation of TRAIL and its receptors DR4 and DR5 in human placenta during pregnancy.
方法免疫组织化学结合图像分析定量方法观察TRAIL及其DR4、DR5受体在人胎盘组织的表达及其含量的周龄变化。
Methods Immunohistochemistry and in situ quantification methods were used to observe the expression and the variation of TRAIL and its receptors DR4 and DR5 in human placenta during pregnancy.
方法免疫组织化学结合图像分析定量方法观察TRAIL及其DR4、DR5受体在人胎盘组织的表达及其含量的周龄变化。
应用推荐